查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573874

遺傳性血管水腫 (HAE) 治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Hereditary Angioedema (HAE) Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 167 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球遺傳性血管水腫治療市場估值為41 億美元，預計2024 年至2032 年複合年成長率為9.2%。進步，特別是增強遺傳性測試。這些進步導致更多的診斷和越來越多的患者尋求有效的治療。

例如，《罕見疾病顧問報告》強調，在美國，HAE 發作每年導致15,000-30,000 人次到急診室就診。 ，其中不到38症狀出現後 1-3 年內獲得準確診斷的患者百分比。醫療保健專業人員和患者的意識不斷增強，加上標靶治療的突破，預計將推動市場成長。這些突破包括新的補體抑制劑和緩激肽 B2 受體拮抗劑。

標靶治療領域的持續創新，尤其是新型補體抑制劑和緩激肽 B2 受體拮抗劑，正在推動市場擴張。這些療法比傳統療法具有卓越的功效和安全性，對患者和醫療保健提供者都有吸引力。例如，2024 年 5 月，Ionis Pharmaceuticals, Inc. 報告了其 3 期 OASIS-HAE 和 OASISplus 研究的可喜成果。他們的藥物 donidalorsen 表現出每月 HAE 發作率顯著且持續的降低，即使在一年後，無論患者是每月還是每兩個月服藥一次，發病率都有超過 90% 的改善。藥物開發的這些進步正在拓寬 HAE 的治療前景，進一步促進市場成長。

整個 HAE 治療市場根據治療類型、給藥途徑、年齡層和地區進行分類。

2023年，C1酯酶抑制劑領域引領市場，營收達18億美元。隨著醫療保健專業人員和公眾對 HAE 的認知和理解不斷增強，早期診斷和治療變得更加普遍。這種意識的激增增加了對 C1 酯酶抑制劑的需求，C1 酯酶抑制劑是急性 HAE 發作的首選治療方法。 C1 酯酶抑制劑因其安全性和有效性而受到認可，比更廣泛的治療選擇越來越受到青睞。此外，它們擴大用於 HAE 患者的長期預防，突顯了一個重要的市場趨勢，特別是隨著該行業從反應性護理轉向預防性護理。

預計到 2032 年，成人市場將達到 51 億美元。診斷數量的激增刺激了對成人需求的治療的需求。由於對自身病情有更深入的了解，成年患者往往會更主動地尋求治療，他們受益於患者倡導團體和教育活動的努力，進一步擴大了這一人群對 HAE 治療的需求。

到 2023 年，北美將佔據 46.8% 的重要佔有率，預計將保持其在全球遺傳性血管水腫治療市場的主導地位。該地區（尤其是美國）強大的研發基礎設施促進了新型 HAE 療法的快速開發和批准。頂級製藥公司、受人尊敬的學術機構和先鋒研究組織的集中催化了創新，將先進的治療方法引入市場。此外，針對 HAE 等罕見疾病的專科診所和治療中心的激增也增加了患者獲得護理的機會。這些中心配備了最新的療法，在確保患者及時有效的治療方面發揮關鍵作用，從而促進了市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • HAE標靶治療的進展
      • HAE 發生率增加
      • 診斷技術的進步
      • 日益向個人化醫療轉變
    • 產業陷阱與挑戰
      • 新 HAE 療法的嚴格監管要求
      • 治療費用高
  • 成長潛力分析
  • 監管環境
  • 管道分析
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • C1-酯酶抑制劑
  • 緩激肽 B2 受體拮抗劑
  • 激肽釋放酶抑制劑
  • 其他治療類型

第 6 章：市場估計與預測：按給藥途徑，2021 年至 2032 年

  • 主要趨勢
  • 口服
  • 注射用

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

  • 主要趨勢
  • 兒科
  • 成人
  • 老年科

第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Attune Pharmaceuticals
  • BioCryst Pharmaceuticals, Inc.
  • Biomarin
  • CSL Behring LLC
  • Intellia Therapeutics
  • Ionis Pharmaceuticals
  • KalVista Pharmaceuticals, Inc.
  • Pharming Healthcare, Inc.
  • Pharvaris
  • Takeda Pharmaceutical Company Ltd
簡介目錄
Product Code: 11102

The Global Hereditary Angioedema Therapeutics Market was valued at USD 4.1 billion in 2023 and is projected to grow at a CAGR of 9.2% from 2024 to 2032. Key drivers include heightened awareness of hereditary angioedema (HAE) and advancements in diagnostic technologies, particularly enhanced genetic testing. These advancements lead to more diagnoses and an increasing patient population seeking effective treatments.

For example, the Rare Disease Advisor Report highlights that HAE episodes account for 15,000-30,000 emergency department visits annually in the U.S. A survey of U.S. physicians indicated that diagnosing HAE can take anywhere from 0-6 months to over a decade, with less than 38% of patients receiving an accurate diagnosis within 1-3 years of symptom onset. Growing awareness among healthcare professionals and patients, combined with breakthroughs in targeted therapies, is expected to propel market growth. These breakthroughs include new complement inhibitors and bradykinin B2 receptor antagonists.

Ongoing innovations in targeted therapies, especially new complement inhibitors and bradykinin B2 receptor antagonists, are fueling market expansion. These therapies, boasting superior efficacy and safety over traditional treatments, appeal to both patients and healthcare providers. For instance, in May 2024, Ionis Pharmaceuticals, Inc. reported promising outcomes from its Phase 3 OASIS-HAE and OASISplus studies. Their drug, donidalorsen, showcased a marked and sustained reduction in monthly HAE attack rates, with over 90% improvement even after a year, regardless of whether patients were dosed monthly or bi-monthly. Such advancements in drug development are broadening the therapeutic landscape for HAE, further bolstering market growth.

The overall HAE therapeutics market is divided based on treatment type, route of administration, age group, and region.

In 2023, the C1 esterase inhibitors segment led the market with revenues reaching USD 1.8 billion. As awareness and understanding of HAE have grown among both healthcare professionals and the public, earlier diagnoses and treatments have become more common. This surge in awareness has heightened the demand for C1 esterase inhibitors, the go-to treatment for acute HAE attacks. Recognized for their safety and effectiveness, C1 esterase inhibitors are increasingly preferred over broader treatment options. Furthermore, their rising use for long-term prevention in HAE patients underscores a significant market trend, especially with the industry's shift from reactive to preventive care.

The adult segment is projected to hit USD 5.1 billion by 2032. Thanks to advancements in diagnostics and heightened awareness, a growing number of adults are being accurately diagnosed with HAE. This surge in diagnoses has spurred demand for therapies tailored to adult needs. Adult patients, often more proactive in their treatment pursuits due to a deeper understanding of their condition, benefit from the efforts of patient advocacy groups and educational campaigns, further amplifying the demand for HAE therapies in this demographic.

North America, holding a significant 46.8% share in 2023, is poised to maintain its dominance in the global hereditary angioedema therapeutics market. The region's robust R&D infrastructure, particularly in the U.S., has facilitated the swift development and approval of novel HAE therapies. The concentration of top-tier pharmaceutical firms, esteemed academic institutions, and pioneering research organizations has catalyzed innovation, ushering advanced treatments into the market. Additionally, the proliferation of specialized clinics and treatment centers for rare diseases like HAE enhances patient access to care. These centers, equipped with the latest therapies, play a pivotal role in ensuring timely and effective treatment for patients, thereby bolstering market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Advancement in targeted therapies for HAE
      • 3.2.1.2 Increasing incidence of HAE
      • 3.2.1.3 Advancement in diagnostic technologies
      • 3.2.1.4 Increasing shift towards personalized medicine
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory requirements for new HAE therapies
      • 3.2.2.2 High cost of treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 C1-esterase inhibitor
  • 5.3 Bradykinin B2 receptor antagonist
  • 5.4 Kallikrein inhibitor
  • 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
  • 7.3 Adult
  • 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Drug store and retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Attune Pharmaceuticals
  • 10.2 BioCryst Pharmaceuticals, Inc.
  • 10.3 Biomarin
  • 10.4 CSL Behring LLC
  • 10.5 Intellia Therapeutics
  • 10.6 Ionis Pharmaceuticals
  • 10.7 KalVista Pharmaceuticals, Inc.
  • 10.8 Pharming Healthcare, Inc.
  • 10.9 Pharvaris
  • 10.10 Takeda Pharmaceutical Company Ltd